Mumbai, March 31 -- Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug

Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment

of solid tumors.

"SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally." said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC f...